Get Premium to unlock powerful stock data
NAS:OCUP (USA)  
Ocuphire Pharma Inc logo

Ocuphire Pharma Inc

$ 1.97 +0.08 (+4.23%) 10:08 PM EST
P/E:
At Loss
P/B:
2.19
Market Cap:
$ 38.15M
Enterprise V:
$ 17.43M
Volume:
40.76K
Avg Vol (2M):
133.57K
Also Trade In:
Volume:
40.76K
Market Cap $:
38.15M
PE Ratio:
At Loss
Avg Vol (2-Month):
133.57K
Enterprise Value $:
17.43M
PB Ratio:
2.19
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Ocuphire Pharma Inc
NAICS : 325412 SIC : 2834
37000 Grand River Avenue, Suite 120, Farmington Hills, MI, USA, 48335
Description
Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.
Name Current Vs Industry Vs History
Cash-To-Debt 90.14
Equity-to-Asset 0.84
Debt-to-Equity 0.01
Debt-to-EBITDA -0.01
Piotroski F-Score N/A/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.59
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 55.26
9-Day RSI 50.16
14-Day RSI 47.04
6-1 Month Momentum % -43.05
12-1 Month Momentum % -57.35

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.37
Quick Ratio 6.37
Cash Ratio 6.03

Dividend & Buy Back

Name Current Vs Industry Vs History

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -4079.29
Net Margin % -4121.22
ROE % -131.31
ROA % -113.28
ROIC % -13407.92
ROC (Joel Greenblatt) % -220609.09
ROCE % -131.27

Financials (Next Earnings Date:2022-08-12 Est.)

OCUP's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:OCUP

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.589
EPS (TTM) ($) -1.47
Beta 0
Volatility % 45.69
14-Day RSI 47.04
14-Day ATR ($) 0.119412
20-Day SMA ($) 1.9785
12-1 Month Momentum % -57.35
52-Week Range ($) 1.7801 - 5.5
Shares Outstanding (Mil) 19.36

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 9999
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ocuphire Pharma Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More